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Abstract 
 
The level of polydispersity or aggregation in a protein population is an important 
factor to consider when performing conjugation or labeling reactions.  In such reactions, 
the more aggregated portions of a polydispersed protein population have a tendency to be 
less labeled—or have a lower degree of labeling (DOL)—than the more highly labeled, 
less aggregated portions of the population.  The mechanism by which this differential 
labeling occurs is thought to work as follows:  When conjugating a protein to a detection 
mechanism or other conjugate of interest, the reaction, as it occurs in solution, can be 
visualized as taking place in a vast, empty space.  In such a scenario, each particle in the 
reaction is very dilute relative to the total volume of the reaction.  Therefore, each protein 
particle in the reaction has a similar, average number of chemical interactions with the 
conjugate molecules in the reaction, regardless of the protein particle’s size or number of 
subunits.  The number of molecular interactions a particle will have during the 
conjugation reaction is very unlikely to be affected by the number of subunits it contains; 
conversely, however, the number of subunits will have a considerable effect on the DOL 
calculated for a given set of the dispersed population.   
If we assume the monomeric portion of a dispersed protein population receives an 
average of one label during conjugation, then we would also assume that the more 
aggregated portion of the population will receive the same average number of labels and 
have the same number of labels per particle.  However, because the two sets of particles 
(monomeric and aggregated) do not contain the same number of subunits, the degree of 
 
 
labeling will differ quite significantly.  This is because the amount of protein present is 
inversely related the degree of labeling; as the protein concentration increases, the degree 
of labeling decreases.     
The study described in this thesis seeks to demonstrate that the different 
polydispersed populations present in a conjugate solution will have significant 
differences in their DOL with the smaller, less aggregated particles in the conjugate 
having a DOL than larger, more aggregated particles.  To do this, two special batches of 
fluorescent protein conjugates were prepared, one labeled with Alexa Fluor 594 and the 
other with Alexa Fluor 488.  Both of these conjugates were fractionated by size and the 
fractions of interest were promptly assayed to determine their DOL and to compare the 
level of labeling in each of the polydispersed populations in the conjugate sample.  The 
data collected for both prepared conjugates clearly showed that there were considerable 
differences in DOL and a clear trend indicating that the DOL of each species in a 
polydispersed conjugate population decreased as the level of aggregation, or number of 
protein subunits per protein, increased.
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Chapter I 
Introduction 
 
Ligand-binding Assays in Biotech Research: 
When a patient is dosed with a biotherapeutic drug, it is critical for researchers and 
physicians to understand the downstream effects of that treatment on the body in as much detail 
as is possible.  Studies of drug metabolism are known as pharmacokinetic (pK) studies and are 
performed to examine the absorption, distribution, break-down, and excretion of the drug under 
investigation.  Understanding the relationship between the size of a dose, its concentration 
throughout the body and at the intended site of action, and the eventual clearance of the drug 
from the body are all part of the pK assessment. The data obtained from a pK study is often 
useful for the design and format of later clinical trials, as understanding the drug’s absorption 
and distribution in the body after dosing is also very helpful when trying to interpret efficacy and 
safety data generated.  The results of pK studies can also be of use in determining which patients 
may be the best candidates to benefit from a particular drug treatment. 
Understanding pharmacokinetic drug actions in relation to the characteristics of a 
patient’s disease state, or the tissue where the disease is presenting, may have some relevance to 
the eventual success or failure of the treatment.  Therefore, it is always important to evaluate the 
efficacy of the investigational drug, or the nature of any adverse reactions observed during a 
clinical trial, in relation to the physiological characteristics of each individual study participant, 
whether they are a patient or a healthy volunteer (Japanese Ministry of Health, 2001). 
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A critical parameter of pK studies is the accurate measurement of drug concentrations in 
the patient’s serum after dosing.  To measure the concentration of a biotherapeutic drug in a 
complex protein matrix such as serum, the assay used must have the ability to detect the presence 
of the drug without background interference from the many other proteins, peptides, etc. present 
in the sample.  The most effective way to carry out this type of testing is a ligand-binding assay.  
Specific monoclonal antibodies (mAbs) will be developed against the analyte and evaluated for 
their affinity to the analyte of interest to determine which antibody candidates will work best in 
the assay (Leary et al., 2013).   
Below, as seen in Figure 1, is an example of a type of ligand-binding assay format known 
as a sandwich ELISA.  To measure the serum concentration of a biotherapeutic, the drug can be 
specifically ‘captured’ from the serum by an antibody that is specific to a unique epitope on the 
drug itself.  The capture antibody is coated to the well of a 96-well plate, where it will bind any 
drug present in a properly diluted serum sample.  After the capture step, the unbound, excess 
serum and other unwanted proteins present can be washed away, and a second enzyme 
conjugated antibody is added for detection.  The detection antibody is selected to be specific 
against a second, unique epitope on the drug and allows one to accurately detect the amount of 
drug captured in a well after a second wash to remove any excess reagent.  Upon addition of an 
enzyme substrate to ‘develop’ the wells–an enzymatic process which produces an amount of 
color in the well that is proportional to the amount of drug detected–the plate can be read at the 
proper wavelength and the optical response in each well can be compared to a known standard 
dilution to determine sample concentration (Wakankar, 2011). 
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Figure 1: Graphical depiction of an ELISA assay performed in a sandwich format (Wang, 2010). 
The term pharmacodynamics (pD) refers to the relationship between drug concentration 
at the site of action and the resulting effect, including the course of time and the intensity of both 
therapeutic and adverse effects.  In general, the effect of a drug present at the site of action is 
determined by the level to which that drug binds with a receptor.  These receptors may signal 
cell-uptake, initiate downstream cell-signaling, or have any number of other effects on the body.  
The concentration of a drug at the site of the intended receptor typically determines the intensity 
of that drug’s effect.  The level of effect is also modulated by the density of receptors on the 
target cell type, the mechanism of signal transmission in the cell, and any related regulatory 
factors that govern downstream effects.    
An important factor that can affect the pharmacokinetics, and thus the 
pharmacodynamics, of a biotherapeutic treatment is the immune system of the patient being 
dosed.  If a treatment causes an immune reaction in the patient (or, in other words, the treatment 
is immunogenic in the patient), the patient may begin to manufacture specific anti-drug 
antibodies (ADAs) to attack and clear the offending substance from the blood.  This unwanted 
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immune response can reduce the length of time a drug remains functional in the patient’s body 
and thus, reduce its therapeutic value or even neutralize the treatment altogether.  Although every 
patient has the potential to react differently to a given treatment, biotherapeutics can often be 
more immunogenic than their small-molecule counterparts.  This factor makes immunogenicity 
studies especially important for biotherapeutics (Hock et al., 2015). 
In order to study immunogenicity and monitor patients for this type of deleterious 
immune reaction, a type of ligand-binding assay known as an anti-drug antibody assay can be 
employed.  In an ADA assay (Figure 2), similar to the generic sandwich ELISA format 
previously discussed, the drug (a monoclonal antibody for example) can be conjugated to biotin 
and either ‘pulled-down’ onto a streptavidin-coated plate, or otherwise bound to the wells of a 
standard 96-well plate.  Patient serum can then be added to the well and incubated, which will 
result in the binding of any anti-drug antibody present in the serum to the drug captured in that 
well.  The uncaptured excess is subsequently washed away and a second drug conjugate 
(conjugated to a detection mechanism) is then added.  The second conjugate becomes bound in a 
sandwich conformation to the patient’s ADAs and can then be detected in a number of ways, 
depending on the detection mechanism used for the assay platform.  If a patient is found to be 
positive for ADAs, further testing is often run to determine whether the antibodies have a 
neutralizing effect on the drug treatment, or if they merely bind to it without causing any 
discernible changes (Stephan et al., 2011). 
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Figure 2: Generic ADA assay format.                                                                               
(Retrieved from: http://www.gyros.com/user-zone-2/assay-development-guidelines-ada/). 
The ligand-binding assay is the method of choice to quantify levels of a target analyte in 
a complex protein mixture or ‘matrix.’  This type of assay has only grown in prominence as drug 
companies increasingly shift towards the development and manufacture of biotherapeutics.   
Ligand-binding reagents (critical reagents), when used in an appropriate assay format, are the 
most effective method to uniquely bind and identify an analyte of interest amongst a multitude of 
other components in a complex matrix like human serum.  This type of specific interaction 
allows a researcher to detect the presence of the drug or ADA in patient serum without 
interference (Pollard, 2010; Wakankar et al., 2011). 
 
Antibody Development and Purification: 
Monoclonal antibodies are generally produced in cell culture by fusing myeloma cells to 
either mouse spleen cells or rabbit B-cells, which have been immunized with an antigen of 
interest.  Upon immunization, these hybrid myeloma cells will produce identical copies of a 
single antibody against a specific epitope on the analyte that was used to immunize the animal.  
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In general, when developing mAbs for use as critical reagents in an LBA, several mAb 
candidates will be grown in culture and evaluated for use in the assay.  The antibodies 
themselves are excreted into the supernatant by the cultured cells and require subsequent 
purification and buffer exchange prior to further use in assay development.   
For mAbs (IgG), the easiest and most effective method for purification is a Protein 
A/Protein G column.  Protein A and Protein G are immunoglobulin-binding proteins which can 
be recombinantly expressed and used to purify, immobilize and detect immunoglobulins.  Each 
of the immunoglobulin-binding proteins has a different binding profile with respect to the 
portion of the antibody that is recognized and the isotype that it will bind.  These proteins, when 
bound in a purification column, can be used to bind and extract all of the IgG present in a cell 
culture supernatant (or animal serum), thus purifying out the IgG portion (the mAbs themselves, 
in this case) from the unwanted culture media and metabolic waste that is also present in the 
supernatant.  Upon elution from the column, only the desired IgG mAbs will be present in the 
elution buffer used.  A final buffer exchange step can then be performed to facilitate stable 
storage (Wikipedia Contributors, 2013). 
Polyclonal antibodies (pAbs), obtained from the serum of immunized animals, require a 
further purification step.  After collecting the serum of an animal that has been inoculated against 
the target of interest, the polyclonal IgG in the serum can be similarly purified using a Protein 
A/Protein G column.  Once this step is complete, all of the IgG present in the animal, or ‘whole 
IgG’ will have been collected from the serum, including some portion that is specific to the 
target of interest, which must then be purified from the remaining, non-specific IgG population.  
In order to select out only those IgGs specific to the desired target, an affinity purification step 
must be performed.   
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Small-scale affinity purification, such as that done for the production of critical reagents, 
is often carried out using a commercially available column resin, which can be coupled to the 
target of interest.  The whole IgG portion, collected from the prior Protein A/G purification step, 
is then passed over the coupled affinity resin and the specific pAbs will be bound to the target; 
this allows the unbound, non-specific portion to be easily washed away.  After washing the 
unbound antibodies from the column with several buffer rinses, the specific polyclonal IgG is 
then eluted using a low pH solution (pH ~2.4) and then immediately pH neutralized upon 
collection.  The collected antibodies can then be buffer exchanged and stored for later use 
(Filntisi et al., 2014). 
 
Chemistry of Protein Conjugation: 
The process of protein conjugation involves the linking of proteins or other biological 
molecules to conjugate molecules through a chemical reaction.  This includes the conjugation of 
antibodies, enzymes, peptides, or other biologically active molecules to any type of molecule that 
adds a desirable property.  These molecules may include radioactive tags, toxins, enzymes or 
fluorescent compounds, among many others.  The most common methods used to carry out such 
protein conjugations involve amine chemistry and can easily be performed by a single analyst in 
a lab (Breen et al., 2016; Sesay, 2003). 
One of the most common reactive groups found on proteins is the aliphatic ε-amine of the 
amino acid group lysine.  Nearly all antibodies have lysine residues in abundance, and it is 
therefore, a useful target when performing conjugations.  The amines in lysine become 
reasonably nucleophilic above pH 8.0 and can react easily with a variety of reagents to form 
stable bonds.  These coupling reactions may be performed at multiple challenge ratios (or 
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differing conjugate dilutions) in an attempt to induce the proper level of conjugation (Sesay, 
2003). 
Common antibody-amine conjugation reaction: 
Antibody-NH2 + Z-B → 
Antibody-NHB + Z-H (1) 
Other reactive amine groups found on proteins are the α-amino groups of N-terminal 
amino acids.  The α-amino groups are less basic than lysine residues and are reactive at a lower 
pH (approximately 7.0).  Performing a conjugation reaction at a pH of 10, for example, will 
render these N-terminal sites non-reactive.  Conversely, carrying out the reaction at a lower pH 
will allow the N-terminal amino groups to be to be targeted.  Since either N-terminal amines or 
lysine residues are almost always present, and because these sites can be conjugated with relative 
ease, these amines provide the most commonly employed method of protein conjugation (Filntisi 
et al., 2014; Sesay, 2003). 
In general, when performing protein conjugation reactions of this type, one must be 
mindful of the statistical and somewhat random nature of such reactions.  Thought must be given 
to the potential effect the conjugation reaction itself can have on the final conjugated product.  
The exact sites of conjugation cannot be strictly controlled and may vary from one conjugate 
molecule to another.  Whether each potential conjugation site is chemically “equal” is unknown, 
as some sites may affect binding affinity, potential epitopic regions, or other chemical properties 
of a mAb where alternative sites may not.   
In such reactions, the inherent uncertainty very often leads to a heterogeneous, 
polydispersed population of conjugates, some with different conjugation sites, degrees of 
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labeling, and possibly, a somewhat altered set of chemical properties.  The conjugation process 
has the potential to perturb the conjugated protein’s tertiary structure in subtle ways, some of 
which may induce changes to the hydrophobicity, charge or level of aggregation (see Figure 4 – 
Panel A).  When preparing critical reagents for an important LBA, it is helpful to keep these 
factors in mind.  Once reagent conjugation has been completed, it is always good practice to 
measure the binding affinity of the final conjugate against that of the unconjugated Ab to ensure 
proper binding was retained (Filntisi et al., 2014, Wakankar et al., 2011). 
 
Area of Specific Interest: 
Custom-made, critical reagents designed for use in testing are usually produced in 
relatively small batches, either in-house or through a contract partner.  Reagents of this type are 
required to perform ligand-binding assays (LBA), such as anti-drug antibody (ADA) assays, in 
the modern lab.  The term critical reagent describes an essential component of a ligand-binding 
assay whose unique characteristics directly impact assay performance.  Throughout 
biotherapeutic drug development and the various clinical phases, LBA and ADA assays are run 
to assess and monitor several crucial parameters of a given biotherapeutic treatment, such as pK, 
pD and immunogenicity.   
Ligand-binding assays are the primary methods used to quantify biotherapeutics, 
biomarkers and anti-drug antibodies to support biotherapeutics development.  Ligand-binding 
assays take advantage of an antibody’s or receptors unique specificity for its target to measure 
analytes, even in the presence of a complex matrix or background.  Researchers may use an 
antibody that was raised against a specific epitope, or set of epitopes, on the analyte of interest 
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(e.g., the biotherapeutic drug itself, the drug’s target, etc.) (O’Hara et al., 2012; Wakankar, 
2011).  The specificity of the antibodies employed in the assay allows one to measure the analyte 
effectively, even when it is mixed within a matrix of hundreds or thousands of other proteins (as 
it would be in a patient’s serum), with very little interference.  These Abs are referred to as 
critical reagents because ligand-binding assays cannot be performed without them.  Thus, the 
continued specificity, stability and overall quality of these critical reagents are directly related to 
the accuracy and precision of the assay and the quality of any data collected from it.  Therefore, 
assays of this type necessitate a thorough and accurate physiochemical characterization of any 
critical reagent produced for testing to ensure a high degree of quality (O’Hara et al., 2013). 
The production of critical reagents often involves the conjugation of a source protein to 
either a capture (e.g., biotin) or a detection mechanism (e.g., a fluorescent label or dye conjugate) 
for functional use in an assay.  The source protein could be a specific monoclonal antibody 
cultured in a lab, a mass produced biotherapeutic like a mAb or enzyme, like many of the biotech 
drugs currently on the market, or a polyclonal antibody that has been purified from the serum of 
an animal previously inoculated against the target of interest.  Animal pAbs, in their native state, 
are often utilized as positive controls in ligand-binding assays (O’Hara et al., 2013).  
As a biochemical process, the statistical nature of protein conjugation often introduces 
polydispersity and other forms of physical heterogeneity into the conjugated population.   
Polydispersity, or heterodispersity, is a term that describes the distribution of particles of varied 
sizes which are dispersed in a colloidal solution.  Polydispersity can proceed naturally over time 
or occur more rapidly due to changes in pH, perturbation of the protein’s tertiary structure by the 
conjugation process, or by induced hydrophobic or ionic forces related to the conjugation.  Some 
of the proteins in the solution may aggregate, leading to a mixed population of monomeric, 
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dimeric, trimeric, etc. aggregations of protein subunits (Frka-Petesic et al., 2016). This raises a 
question for those tasked with producing high quality critical reagents:  What effect does the 
polydispersity of a source protein have when used as the basis for the production of a conjugated 
critical reagent?  Could this potentially affect the degree to which the source protein is tagged by 
the intended conjugate, also known as degree of labeling (DOL)?  What affect would such 
phenomena have on the results of an LBA for which the critical reagent is intended?   
In practice, critical reagents are usually found to be aggregated to some degree, and the 
DOL of the dispersed populations may vary.  Depending on the nature of the purification and 
conjugation procedure used, the level of aggregation and polydispersity can differ greatly from 
one protein to another, taking a wide range of values.  The working theory regarding the effect 
that polydispersity has on the product of a conjugation reaction presented in this thesis is as 
follows:   
When conjugating a protein to a detection mechanism, or any other conjugate of 
interest, the reaction, in solution, can be visualized as occurring in a vast, empty 
space.  In such a scenario, each particle in the reaction is very dilute relative to the 
total volume of the reaction.  Therefore, each protein particle in the reaction has a 
similar, average number of chemical interactions with the conjugate molecules in the 
reaction, regardless of the protein particle’s size or number of subunits.  When 
comparing the size of small protein particles (≤150,000 KDa), such as a single 
enzyme or antibody, the difference in “size” between a single and multi subunit 
“aggregate” is quite negligible relative to the total volume of the conjugation reaction.  
The number of molecular interactions a particle will have during the conjugation 
reaction is very unlikely to be affected by the number of subunits it contains.  
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However, significant levels of aggregation could absolutely affect the degree of 
labeling in a polydispersed conjugate population precisely because all of the particles 
in the reaction are likely to average the same number of molecular interactions during 
the reaction.  If the monomeric portion of the dispersed protein population receives 
one label on average, the aggregated portion will have the same number of labels, 
regardless of how many subunits the particle contains.  However, because the 
particles do not contain the same number of subunits, the degree of labeling may 
differ significantly.  This is because the amount of protein present is inversely related 
the degree of labeling; as the protein concentration increases, the degree of labeling 
decreases. 
In Figure 3, a protein-conjugate sample under analysis was separated by size exclusion 
chromatography (SEC) on a Waters Alliance HPLC instrument.  In SEC analysis, the intact, non-
denatured protein sample is passed through a column packed with specialized beads under high 
pressure.  The column is designed to retain smaller particles for a longer period of time than 
larger particles, in order to separate them by their size vs. their retention time, as depicted by the 
x-axis.  The largest particles in the solution take a shorter path through the column packing 
material and are eluted first (farther to the left on the x-axis), with a lower retention time, while 
the smaller particles take longer paths through the column packing material and are eluted later, 
with increasing retention times according to a decreasing size gradient.  After separation by size, 
the separated sample passes through a series of detectors and can detected simultaneously for 
absorbance at 280 nm for protein content and aggregation, and also at the proper excitation and 
emission wavelengths for fluorescence response in accordance with the fluorescent tag used to 
13 
 
produce the conjugate being assayed.  In Figure 3, the two chromatograms, one received from 
each detector, are overlayed and normalized to the y-axis for comparison.   
All SEC data is interpreted in a relative manner according to the percent area under each 
peak.  Shown by the black-colored A280 nm trace, the sample in Figure 3 has a large aggregated, 
high molecular weight (HMW) portion relative to the amount of smaller constituents in the 
overall polydispersed size population.  However, when comparing the information received from 
each detector, the aggregated portion of the reagent appears to have a much lower fluorescence 
response per amount of protein present (according to the blue-colored trace), leading to the 
inference that this HMW population may have lower DOL in comparison to the monomeric or 
dimeric portions of the reagent.  Thus, depending on the severity of the aggregation and the 
potential disparity in DOL of the polydispersed populations, this phenomenon could potentially 
have an effect on the sensitivity or precision of any ligand-binding assay in which this lot of 
reagent is to be used.  For example, assume our critical reagent contains an aggregated and less-
labeled, dimeric portion, which retains its biological activity in the assay.  That dimeric portion 
of the critical reagent can bind two-fold the number of target ligands as the monomeric portion, 
yet it will provide only an equal response upon detection, leading to an underestimation of the 
concentration of our target and compromising the accuracy of our results.  
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Chapter II 
Materials and Methods 
 
 For the purposes of this thesis, two conjugates were identified through preliminary work, 
which were thought to be good candidates for studying the effects of protein aggregation on the 
DOL of polydispersed protein conjugate populations.  Due to restraints around corporate privacy, 
these conjugates can only be referred to as ERT1-AF594 and ERT2-AF488, meaning enzyme 
replacement therapy 1 conjugated to Alexa Fluor 594 and enzyme replacement therapy 2 
conjugated to Alexa Fluor 488 respectively.  These two enzyme replacement therapies (ERTs) 
are products developed by the Sanofi Genzyme Company and are conjugated to various 
fluorescent reporters for the purpose of study in clinical assays, such as assays for cell uptake 
and neutralizing anti-drug antibody.  A lot of each of these ERT conjugates was specifically 
prepared for use in this study. 
 
Conjugation of ERT1-AF594: 
 Two 20 mg vials of ERT1 drug substance were reconstituted to a concentration of 10 
mg/mL with DI water.  The reconstituted ERT1 was then desalted using a 10 mL, 7K MWC 
Zeba Spin Column (Thermo Science) and buffer exchanged into a 0.1 M Sodium Bicarbonate 
solution (pH 8.3) using a second, 10 mL, 7K MWC Zeba Spin Column that was pre-washed 4x 
with 0.1 M Sodium Bicarbonate solution (pH 8.3).  The desalted and buffer exchanged ERT1 
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was then adjusted to 5 mg/mL using the same bicarbonate buffer as above and stored at 2-8°C 
while the Alexa Fluor 594 conjugate material was prepared.  All spins were done at 1000 RCF 
for 2 minutes at ambient temperature.   
 An appropriate amount of 5 mg/mL Alexa Fluor 594 (AF594), a commercial reagent sold 
by Life Technologies, was prepared to perform the conjugation at molar ratio of 20 (20 mol dye 
to 1 mol protein).  Two 5 mg AF 594 aliquots were reconstituted with 500 uL DMSO per aliquot, 
mixed well and protected from light prior to conjugation.   
 In a dark area, the reconstituted AF594 was added dropwise to the ERT1 in 0.1 M 
Sodium Bicarbonate solution (pH 8.3) while stirring vigorously.  The conjugate mixture was 
then protected from light and incubated at 2-8°C for 1 hour on a mixer.   
 After stirring at 2-8°C for an hour, the final conjugate was immediately desalted into 1x 
PBS (pH 7.2) on an AKTA Explorer instrument using a 5K MWC HiPrep 26/10 Desalting 
Column (GE Healthcare) flowing at 5.0 mL/min to remove any free, unconjugated dye 
molecules and to buffer exchange the ERT1-AF594 into 1x PBS for storage.  (Refer to Figure 5) 
 
Conjugation of ERT2-AF488: 
 Six vials of ERT2 drug substance were obtained and concentrated using 6 9K MWC, 
7mL Pierce Protein Concentrators (Thermo Science) that had been prewashed with 6 mL DI 
water and spun at 2000 RCF for 10 minutes.  Once the ERT2 was added to each concentrator, 
they were spun at 2500 RCF for 25 minutes at ambient temperature.  After removing the 
concentrated ERT2 from each concentrator, the concentrators were loaded with 60 uL DI water 
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and allowed to sit at ambient temperature for 10 minutes, after which the 60 uL of water was 
removed and added to the concentrated ERT2 samples and stored at 2-8° C.  A BCA assay was 
then performed to determine the final protein concentration of the concentrated ERT2 samples. 
 Each ERT2 sample was then diluted to a concentration of 5 mg/mL with DI water based 
on the results of the previous BCA assay.  Then, with the ERT2 samples on ice, the pH of each 
sample was brought to a pH of 9.0 through addition of a 1M Sodium Bicarbonate solution (pH 
9.4) and stored at 2-8°C.  
 An appropriate amount of 10 mg/mL Alexa Fluor 488 (AF488), a commercial reagent 
sold by Life Technologies, was prepared to perform the conjugation at molar ratio of 25 (25 mol 
dye to 1 mol protein).  The AF488 aliquots were reconstituted with 500 uL DMSO per aliquot, 
mixed well and protected from light prior to conjugation.      
 In a dark area, the reconstituted AF488 was added dropwise to the ERT2 at pH 9.0 while 
stirring vigorously.  The conjugate mixture was then protected from light and incubated at 2-8°C 
for 1 hour on a mixer. 
 After stirring at 2-8°C for an hour, the final conjugate was immediately added to a 10,000 
MWC Slide-A-Lyzer™ dialysis cassette (Thermo Science) and dialyzed into 4L of pre-chilled 
1x PBS at 2-8°C.  The pre-chilled 1x PBS was subsequently changed 5x with fresh, pre-chilled 
1x PBS over a 60 hour period, with at least 4 hours between each buffer change.  After 
completing the 5 rounds of dialysis, the ERT2-AF488 was harvested and protected from light for 
storage. 
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Fractionation of ERT1-AF594 and ERT2-AF488 on AKTA Explorer: 
 To study the individual, poly dispersed populations in each prepared conjugate, each ERT 
conjugate was fractionated into 0.5 mL fractions using an AKTA Explorer instrument (GE 
Healthcare), and collected using an associated fraction collector and 3 generic 96-deepwell 
plates.  A GE HiPrep 26/60 Sephacryl™ S-2000 semi-analytical SEC column (GE Healthcare) 
was used to fractionate the samples, flowing at 5 mL/min in 100 mM Sodium Phosphate, 200 
mM L-Arginine buffer (pH 6.8).  (Refer to Figures 6 and 7)   
 
Determination of Degree of Labeling: 
A NanoDrop 2000 instrument was used to determine the final protein concentration, dye 
absorbance and DOL of selected fractions from the previous experiment.  The NanoDrop 2000 
instrument functions almost identically to a spectrophotometer, but requires one to use much less 
sample per measurement (2 uL).  Select fractions of each ERT conjugate were measured on the 
instrument to determine the protein concentration and dye absorbance for the given fractions in 
order to specifically determine the DOL for each.  (Refer to Tables 2 and 3) 
 
Confirmation of Proper Separation and Fractionation by Analytical Size Exclusion HPLC: 
 The final step of the study was to confirm through analytical SEC that the fractions 
collected had, in fact, been properly separated by size and that the polydispersed populations had 
indeed been isolated or enriched in the fractions tested.  In other words, this technique was used 
to determine which size populations had been captured or enriched in each fraction of interest.  
(Refer to Figures 7-10) 
18 
 
The SEC testing was performed on a Waters Alliance HPLC system using a Waters 300 
mm Xbridge BEH200 (or BEH450) SEC column using a 100 mM Sodium Phosphate, 200 mM 
L-Arginine mobile phase (pH 6.8).  A protein load of 20 ug per injection was targeted based on 
the protein concentration data collected for each fraction in the previous study using the 
NanoDrop 2000.  The samples were run at a flow rate of 1 mL/min for 20 minutes and detected 
at 280 nm. 
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Chapter III 
Results: 
 
Preliminary Data: 
 
Figure 3: Here we see an overlay of SEC data showing the 280 nm trace and the fluorescence 
trace for a fluorescent dye conjugate.  The 280 nm profile is shown in black and the fluorescence 
profile is superimposed in blue.  Overlaying the 280 nm and fluorescence data allows us to 
clearly visualize the significant discrepancy between the levels of fluorescence signal given off 
by the different polydispersed populations in the conjugate sample.  The more aggregated portion 
of the dispersed population appears to be considerably less labeled than the less aggregated 
portion of the sample. 
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Figure 4A:  Analytical SEC of ERT2 drug product (black) and ERT2-AF488 conjugate 
(red), both detected at 280 nm.  20 ug of each protein was separated on a Waters 300mm 
Xbridge BEH450 SEC column using 100 mM Sodium Phosphate, pH 6.8 mobile phase.  
Quantification of peak areas is summarized in Table 1.  Note the significant increase in 
aggregation from before and after the conjugation reaction.  NOTE:  The overlay of the 
initial, unlabeled ERT2 drug product, superimposed against the final product of the 
conjugation reaction, is a very effective way to visualize how severely the conjugation 
reaction can affect the polydispersity of the sample.  The initial drug product (shown in 
21 
 
black in panel A) is a single monomeric peak with a very small amount of LMW species.  
However, the final conjugation product (shown in red in panel A) shows significantly 
increased levels of aggregation and polydispersity, the apparent result of some aspect of 
the conjugation reaction itself. 
Figure 4B:  Analytical SEC of ERT2-AF488 dye conjugate.  Due to a path length of 
several centimeters between detectors, the retention time of all Ex495/Em519 
fluorescence peaks (blue lines) is very slightly delayed relative to the corresponding 280 
nm peaks (black lines). The y-axis is normalized such that both fluorescence and 280 nm 
channels are displayed on the same scale.  Proteins were separated on a Waters 300mm 
Xbridge BEH450 SEC column using 100 mM Sodium Phosphate, pH 6.8 mobile phase 
(20 ug per injection for A280 detection; 1.0 ug per injection for fluorescence detection).  
Quantification of peak areas is summarized in Table 1. 
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% of Total Peak Area 
 
 
A280 (total protein) 
Em519 (fluor. 
Protein) 
Fluor/A280 Ratio 
Sample 
Main 
Peak 
HMW 
Peaks 
Main 
Peak 
HMW 
Peaks 
Main 
Peak 
HMW 
Peaks 
ERT2 drug 
product 
97.84 N/A N/A N/A N/A N/A 
ERT2-AF488 
(corrected for 
free dye peak) 
23.73 61.69 84.84 15.16 3.575 0.246 
 
Table 1:  Summary of analytical SEC data generated for ERT2 drug product and ERT2-AF488 
dye conjugate protein.  The percent of total peak area is reported for both A280 and 
Ex495/Em519 channels, and the fluorescence/A280 ratio is calculated from the corresponding 
peak area percentages.  Data is shown with a correction for the free dye associated signal.  The 
free dye peak in the sample accounts for ~27.5% of the total fluorescence area.  The 
chromatographic data is shown in Figure 4B. 
 
NOTE:  A further analysis of the SEC data in Figure 4B was performed in which the ratio of 
peak area percentages (fluorescence vs. A280) was examined for the main and HMW peaks of 
the ERT2-AF488 conjugate (see Table 1).  This ratio should have a value close to 1.0 provided 
that dye-to-protein incorporation is approximately equal in both species.  In our analysis, 
however, the ratio was observed to be far >1 for the main peak (~3.58) and far <1 for the HMW 
peak (~0.25) fractions after correcting for the free dye-associated signal.  We conclude that the 
degree of labeling for the main peak population is substantially higher than that of the HMW 
populations.  
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Conjugation Data (Desalting and Buffer Exchange of ERT1-AF594): 
 
Figure 5:  Chromatogram from the desalting and buffer exchange steps from the ERT1-AF594 
conjugation protocol.  In order to remove any remaining free dye from the final conjugate 
product, the sample was run through a 5K MWC HiPrep 26/10 Desalting Column (GE 
Healthcare) flowing at 5.0 mL/min, and was buffer exchanged into 1X PBS, pH 7.2.  The 
collected portion of the sample is highlighted in the yellow area above.  The remainder of the 
sample (everything outside of the yellow area) was not collected, as this portion contains mostly 
free, unreacted dye.  This Figure is simply intended to help the reader better understand what is 
being done during the buffer exchange step, how the data is displayed and to aid in visualizing 
which portions of the sample are collected and which portions are considered to be waste.    
 Manual run 7:10_UV1_280nm  Manual run 7:10_UV2_254nm  Manual run 7:10_Fractions  Manual run 7:10_Inject
   0
 500
1000
1500
2000
2500
3000
mAU
200 250 300 350 400 450 ml
Waste X1 X2 X3 Waste
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Fractionation Data: 
 
 
 
Figure 6:  Chromatogram of 280 nm signal (shown in blue) and the fractions collected during 
ERT1-AF594 fractionation (shown below the chromatogram in red). ERT1-AF594 conjugate 
was fractionated into 0.5 mL fractions using an AKTA Explorer instrument (GE Healthcare), and 
collected using an associated fraction collector and 3 generic 96-deepwell plates.  A GE HiPrep 
26/60 Sephacryl™ S-2000 semi-analytical SEC column (GE Healthcare) was used to fractionate 
the samples, flowing at 5 mL/min in 100 mM Sodium Phosphate, 200 mM L-Arginine buffer 
(pH 6.8).  
 
For the ERT1-AF594 sample, it was determined that the fractions of interest would be (listed 
from left [larger] to right [smaller] by retention time): 1D2, 1E5, 1E6, 1E7, 1E10, 1F1 and 1F3.  
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Figure 7:  Chromatogram of 280 nm signal (shown in blue) and fractions collected during ERT2-
AF488 fractionation (shown below the chromatogram in red).  ERT2-AF488 conjugate was 
fractionated into 0.5 mL fractions using an AKTA Explorer instrument (GE Healthcare), and 
collected using an associated fraction collector and 3 generic 96-deepwell plates.  A GE HiPrep 
26/60 Sephacryl™ S-2000 semi-analytical SEC column (GE Healthcare) was used to fractionate 
the samples, flowing at 5 mL/min in 100 mM Sodium Phosphate, 200 mM L-Arginine buffer 
(pH 6.8).  Referring to the overlay in Figure 4 – Panel A, we see it is the smaller of the two peaks 
that represents the non-aggregated portion of ERT2.      
For the ERT2-AF488 sample, it was determined that the fractions of interest would be (listed 
from left [larger] to right [smaller] by retention time):  1H9, 1H12, 2A6, 2A9, 2B3, 2B6, 2C6, 
2C9, and 2C12.  
  
 Manual run 8:10_UV1_280nm  Manual run 8:10_Fractions  Manual run 8:10_Logbook  Manual run 8:10_P960_Flow
-0.10
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Data from DOL Determination for ERT1-AF594: 
Fraction: 
Corrected 
Protein 
Concentration 
by A280 
(mg/mL): 
Corrected Dye 
Absorbance by 
A590 (mg/mL) 
DOL 
Ratio of DOL 
vs. Max DOL 
% DOL 
of Max 
DOL 
Unfractionated 
Whole 
1.325 14.1219 7.94 N/A N/A 
1D2 0.03 0.067 1.65 0.177718408 17.77% 
1E5 0.11 1.133 7.67 0.82554101 82.55% 
1E6 0.14 1.505 8.01 0.861608336 86.16% 
1E7 0.1575 1.755 8.30 0.893095683 89.31% 
1E10 0.3067 3.516 8.54 0.918832859 91.88% 
1F1 0.415 4.811 8.63 0.929156111 92.92% 
1F3 0.3 3.743 9.29 1 100.00% 
 
Table 2:  Data and calculated DOL for ERT1-AF594 conjugate fractions of interest.  DOL for 
ERT1-AF594 was determined as follows:   
DOL = [A590] ERT1-AF594 x (Mol. Weight of ERT1) / [ERT1-AF594] mg/mL / ɛ of AF594    
Mol. Weight of ERT1 = 70,000; the absorbance coefficient (ɛ) of AF594 = 94,000 
  
1D2 1E5 1E6 1E7 1E10 1F1 1F3
DOL ERT1-AF594 1.65 7.67 8.01 8.30 8.54 8.63 9.29
1
2
3
4
5
6
7
8
9
10
Degree of 
Labeling 
Fraction 
NOTE: Particle Size is Decreasing Left to Right 
DOL of ERT1-AF594 Fractions 
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Data from DOL Determination for ERT2-AF488: 
Fraction: 
Corrected 
Protein 
Concentration 
by A280 
(mg/mL): 
Corrected Dye 
Absorbance by 
A495 (mg/mL) 
DOL 
Ratio of DOL 
vs. Max DOL 
% DOL 
of Max 
DOL 
Unfractionated 
Whole 
1.645 12.54 8.91 N/A N/A 
1H9 0.08 0.387 5.66 0.45980198 45.98% 
1H12 0.22 1.515 8.05 0.654545455 65.45% 
2A6 0.535 4.694 10.26 0.833948367 83.39% 
2A9 0.58 5.2135 10.51 0.854380335 85.44% 
2B3 0.42 3.9665 11.04 0.897652051 89.77% 
2B6 0.315 3.027 11.23 0.913380481 91.34% 
2C6 0.105 1.012 11.27 0.916096181 91.61% 
2C9 0.115 1.114 11.32 0.920740422 92.07% 
2C12 0.12 1.2625 12.30 1 100.00% 
 
Table 3:  Data and calculated DOL for ERT2-AF488 conjugate fractions of interest.  DOL for 
ERT2-AF488 was determined as follows:   
DOL = [A495] ERT2-AF488 x (Mol. Weight of ERT2) / [ERT2-AF488] mg/mL / ɛ of AF488    
Mol. Weight of ERT1 = 83,000; the absorbance coefficient (ɛ) of AF488 = 71,000 
 
  
1H9 1H12 2A6 2A9 2B3 2B6 2C6 2C9 2C12
DOL ERT2-AF488 5.66 8.05 10.26 10.51 11.04 11.23 11.27 11.32 12.30
5
6
7
8
9
10
11
12
13
Degree of 
Labeling 
Fraction 
NOTE:  Particle Size is Decreasing Left to Right 
DOL of ERT2-AF488 Fractions 
28 
 
Data from Analytical SEC: 
 
Figure 8:  Chromatogram of the unfractionated ERT1-AF594 conjugate run by analytical SEC 
and detected at 280 nm.  Analytical SEC for ERT1-AF594 was performed on a Waters Alliance 
HPLC system, using a Waters 300 mm Xbridge BEH200 SEC column, and a 100 mM Sodium 
Phosphate, 200 mM L-Arginine mobile phase (pH 6.8).  A protein load of 20 ug per injection 
was targeted, running at a flow rate of 1 mL/min for 20 minutes and detected at wavelength of 
280 nm. 
1D2
1E5
1E6
1E7
1E10
1F1
1F3
Figure 9:  Chromatograms of each fraction of interest for ERT1-AF594 run by analytical SEC.  
Analytical SEC for ERT1-AF594 was performed on a Waters Alliance HPLC system, using a 
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Waters 300 mm Xbridge BEH200 SEC column, and a 100 mM Sodium Phosphate, 200 mM L-
Arginine mobile phase (pH 6.8).  A protein load of 20 ug per injection was targeted, running at a 
flow rate of 1 mL/min for 20 minutes and detected at wavelength of 280 nm.  The fractionation 
of ERT1-AF594 was performed on an AKTA Explorer instrument (GE Healthcare) using a 
HiPrep 26/60 Sephacryl™ S-2000 semi-analytical SEC column (GE Healthcare) to fractionate 
the samples while flowing at 5 mL/min in 100 mM Sodium Phosphate, 200 mM L-Arginine 
buffer (pH 6.8). The chromatograms above show that the dispersed, size populations cannot be 
isolated from one another 100%.  However, they do show that the different fractions of interest 
were significantly enriched for different constituents of the polydispersed population. 
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Figure 10:  Chromatogram of the unfractionated ERT2-AF488 conjugate run by analytical SEC 
and detected at 280 nm.  Analytical SEC for ERT2-AF488 was performed on a Waters Alliance 
HPLC system, using a Waters 300 mm Xbridge BEH450 SEC column, and a 100 mM Sodium 
Phosphate, 200 mM L-Arginine mobile phase (pH 6.8).  A protein load of 20 ug per injection 
was targeted, running at a flow rate of 1 mL/min for 20 minutes and detected at wavelength of 
280 nm. 
1H12
2A6
2A9
2B3
2C6
2C9
2C12
1H9
2B6
 Figure 11:  Chromatograms of each fraction of interest for ERT2-AF488 run by analytical SEC.  
Analytical SEC for ERT2-AF488 was performed on a Waters Alliance HPLC system, using a 
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Waters 300 mm Xbridge BEH450 SEC column, and a 100 mM Sodium Phosphate, 200 mM L-
Arginine mobile phase (pH 6.8).  A protein load of 20 ug per injection was targeted, running at a 
flow rate of 1 mL/min for 20 minutes and detected at wavelength of 280 nm.  The fractionation 
of ERT2-AF488 was performed on an AKTA Explorer instrument (GE Healthcare) using a 
HiPrep 26/60 Sephacryl™ S-2000 semi-analytical SEC column (GE Healthcare) to fractionate 
the samples while flowing at 5 mL/min in 100 mM Sodium Phosphate, 200 mM L-Arginine 
buffer (pH 6.8). The chromatograms above show that the dispersed, size populations cannot be 
isolated from one another 100%.  However, they do show that the different fractions of interest 
were significantly enriched for different constituents of the polydispersed population.   
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Chapter IV 
Discussion 
 
Preliminary Data: 
 The preliminary work performed to probe the effects of polydispersity on degree of 
labeling was primarily performed on a Waters Alliance HPLC system using an SEC method 
created for that purpose.  The earliest work was done in a 100 mM sodium phosphate mobile 
phase (at a pH of 6.8).  However, after some development work, 200 mM L-Arginine was added 
to the mobile phase to prevent any hydrophobic (non SEC) interactions from interfering with 
proper separation exclusively by size.   
Repeatedly, during this testing, it was noted that the fluorescent conjugates consistently 
showed a noticeably lower level of fluorescent response coming from higher molecular weight 
peaks when detected at the proper fluorescent excitation and emission wavelengths (Refer to 
Figure 3 and Figure 4B).  It was during these early experiments that the basic idea for this 
research and eventual thesis began to develop:  That the aggregated population of a protein in a 
conjugation reaction has the same number of chemical interactions as the less aggregated 
constituents.  This property is presumed to lead to differing degrees of labeling across the 
polydispersed conjugate population.  Because the fluorescent conjugates produced were readily 
visualized by simple fluorescent detection, it was decided that the study of this phenomena 
would be most effectively elucidated by using fluorescent conjugates.  There are many other 
common conjugate molecules used in ligand-binding assays, but few are as easily detected and 
33 
 
visualized as fluorescent tags.  Thus, for the purposes of this study, fluorescent conjugates were 
produced to best determine any differences in DOL due to polydispersity. 
We visualized the conjugation reaction as occurring in a vast empty space, where each 
dilute particle, regardless of its number of subunits, has the same average number of chemical 
interactions with the dye molecules.  For example, a portion of the dispersed population 
composed of four protein subunits binds the same number of conjugate, dye molecules as the 
population consisting of a single subunit; for simplicity’s sake, let us assume each receives a 
single dye label.  If this is the case, when we compare the 280 nm signal to the levels of 
fluorescent response coming from the different, polydispersed populations of the conjugate, we 
see a vastly unequal response.  If the reaction occurs in the manner assumed above, the aggregate 
with four subunits would result in a DOL of 0.25 while the monomer, while a single protein 
subunit, would have a DOL of 1.0.   
 
Conjugation of ERT 1 and 2: 
 Based on the preliminary data collected, two ERT drugs were chosen as promising 
candidates to study the theory underpinning this thesis.  Both proteins had previously proven to 
be prone to aggregation during conjugation reactions, with Figures 7 and 9 clearly showing how 
heavily aggregated and dispersed these populations of conjugate molecules became after 
labeling.  The ERT1-AF594 and ERT2-AF488 conjugates used for the purposes of this thesis 
were identified based on this shared property.  When performing the conjugation of ERT1 to AF-
594, the final product was desalted and buffer exchanged using an AKTA instrument (refer to 
Figure 5), while the product of the ERT2-AF488 was dialyzed over several days.  This was 
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difference was due to the established procedures for producing these conjugates, which called for 
the two different methods of buffer exchange and free-dye removal. 
 
Fractionation and Collection of Samples: 
To confirm that these polydispersed populations did, in fact, have different degrees of 
labeling, the two lots of fluorescent conjugates were fractionated, by particle size, into 0.5 mL 
fractions using an AKTA Explorer instrument with a GE HiPrep 26/60 Sephacryl™ S-2000 
semi-analytical SEC column.  The fractions of interest were chosen based on their positions 
under the detected peaks (refer to Figures 6 and 7).  Although we were not able to fully separate 
each of the size populations from one another, Figures 8 and 10 help us understand how 
significantly enriched the fractions were for the different size populations.  This being the case, it 
would seem safe to assume that any phenomena or trends observed would be even clearer if a 
better separation technique was identified and optimized to suit our specific purposes.   
It should also be noted that when fractionating a sample by size, any of the aggregates or 
low molecular weight species that are only present in relatively small amounts, will become very 
dilute when fractionated out of the sample.  If our analytical SEC shows that a sample is 5% 
aggregates, we can only hope to collect 5% of the protein in a given fraction.  If the fractionation 
is run with 5 mg of conjugate protein, at best we will collect 0.25 mg of aggregate.  This can be a 
complicating factor when determining degree of labeling as small values in the detected protein 
concentration can prove to be difficult to work with as small differences in protein concentration 
can have relatively large effects on the calculated DOL when the concentrations are very low.  If 
this is the case, it becomes much more important to accurately determine the precise value of that 
low protein concentration. 
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Determination of Degree of Labeling for Polydispersed Populations: 
 In our attempt to definitively calculate the differing DOLs of the polydispersed 
population in our conjugates, multiple replicates and dilutions of each fraction were measured 
using a NanoDrop 2000 spectrophotometer instrument and averaged to calculate the degrees of 
labeling for the conjugate population in each fraction tested.  The reference to “corrected 
absorbance” in this portion of the testing alludes to the fact that we are correcting the raw 
absorbance values obtained from the instrument based on the dilution factor of the sample being 
tested.  Tables 2 and 3 provide very strong evidence that there is, in fact, a significant difference 
in DOL between the different constituents of a polydispersed, protein-conjugate population.  The 
highest molecular weight population found in ERT1-AF594 had only 17.8% the amount of 
labeling as the most labeled population from fraction 1F1.  Further, as the particle size decreases 
(meaning less aggregated, or composed of fewer subunits in this case), the DOL shows a clear, 
rising trend.  The DOL data is supportive of the mechanism proposed here, which leads to 
differing degrees of labeling in polydispersed protein populations, and as presented in this thesis.  
 Once we understand the principals of the labeling reaction presented in this thesis, the 
trend of increasing DOLs as the number of protein subunits decreases is very easy to understand.  
We are simply seeing the effect of each particle in the reaction (not each subunit) having the 
same average number of potential binding interactions during conjugation.  The particles 
themselves end up roughly equally labeled, but because they have differing numbers of subunits 
(or literally, different amounts of protein) their degrees of labeling can differ vastly.  The ratio of 
protein concentration vs. dye absorbance for the aggregates is slightly different than the ratio we 
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find for the less aggregated population.  For ERT1-AF594, this leads directly to a different, 
calculated DOL when used in the equation below: 
DOL = [A590] ERT1-AF594 x (Mol. Weight of ERT1) / [ERT1-AF594] mg/mL / ɛ of AF594    
Mol. Weight of ERT1 = 70,000; the absorbance coefficient (ɛ) of AF594 = 94,000 
 There is an inverse relationship between protein concentration and absorbance.  As the 
protein concentration increases relative to dye absorbance, the resulting DOL we calculate will 
be lower.  Taken with our preliminary data (refer to Figure 3 and 4B), where we saw a vastly 
different amounts of fluorescent response coming from the different size constituents of the two 
conjugate samples, the data from this experiment provides strong confirmatory evidence 
supporting our theory that polydispersity aggregation affect the degree of labeling in protein 
conjugation reactions.  Further, knowing that the level of separation obtained during the 
fractionation step was imperfect—and the resulting fractions were only enhanced for certain size 
constituents, as opposed to isolating these constituents completely—likely indicates that the 
differences in DOL between the size populations is probably more pronounced than the data 
presented here would indicate. 
 
Confirmation of Fraction Content by Analytical SEC: 
 This portion of the study was done as a final, confirmatory step in order to prove that the 
fractions collected during fractionation on the AKTA Explorer contained, or were enriched for, 
conjugate particles of a different size.  As we had hoped, the data obtained showed with relative 
clarity that the fractions were considerably enriched for different and separate size populations.  
For example, fraction 1D2 in Figure 8 shows an excellent level of isolation/enrichment of the 
highest molecular weight constituent of the sample.  The high level of isolation obtained in this 
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fraction may have contributed to how clearly the trend in differing DOLs was shown in the 
fraction (only 17.8% of the most labeled species in that conjugate sample). 
 
Conclusions: 
When interpreted correctly and taken together, the data presented in this thesis provides 
strong evidence for the theory that polydispersity in a protein population leads to differing 
degrees of labeling upon conjugation.  The proposed mechanism presented here, which leads to 
differing DOLs—that all protein particles in the reaction have the same number of chemical 
interactions with conjugate molecules, regardless of their number of subunits—appears to hold 
true after testing.  Although this theory was tested only with fluorescent conjugates (due to the 
limitations in our ability to accurately detect and quantify the DOL of protein conjugates made 
using other labeling/reporting formats), nothing about the data would lead us to believe that this 
scenario would not hold true for a variety of conjugates.  An important question remains 
however:  How this discrepancy in DOL might affect a ligand-binding assay it is used for?   
For example, the ERT1-AF594 conjugate is a critical reagent used in a cellular uptake pK 
assay.  As the cell accumulates the enzyme, it also accumulates fluorescence, which can then be 
read to determine the levels of uptake.  However, if the enzyme population used as a reagent is 
not equally labeled, the accuracy of our results then become questionable, and the critical reagent 
we are depending on to provide solid results could actually be functioning sub optimally in the 
assay itself.  Assuming the cells being assayed can take up the less labeled, more aggregated 
enzymes, we must assume those cells will not display the proper amount of fluorescent response.  
If the cell takes up an aggregate with five subunits, instead of showing five corresponding units 
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of fluorescence (one for each enzyme absorbed), we would see only a single unit of fluorescence, 
leading us to believe that cell has taken up only a single enzyme.  The more severe the 
aggregation is during the conjugation reaction, the more severe the discrepancy in that 
conjugate’s DOLs and the more pronounced the error in the signal level detected becomes.  
These effects could vary in intensity based on the reagent and the assay format being used, but 
would consistently reduce the accuracy and precision that the assay is capable of achieving.  As 
discussed earlier, the quality of critical reagents will directly affect the quality of the ligand-
binding assays they are used for.  Thus, any reduction in the quality and uniformity of our critical 
reagents can be expected to have deleterious effects when used in an assay.   
With this in mind, how can we reduce or prevent this phenomenon from occurring during 
conjugation?  What can be done to help make our DOLs more uniform across a dispersed protein 
population?  According to the labeling mechanism presented in this work, anything that can be 
done to reduce protein aggregation in the reaction should also reduce the discrepancy found in 
the conjugate population’s DOL.  One potential approach to reducing the aggregation which 
takes place during the conjugation is to add a small amount of surfactant to the reaction to reduce 
the protein’s propensity to clump together.   
For example, performing the conjugation reaction in the presence of 0.01-0.05% Tween-
80 could prove beneficial, as it should reduce the number of aggregates formed, and limit the 
amount of polydispersity in the final product.  Another approach to help reduce aggregation 
would be to more carefully control and limit the extremity of the pH used during the conjugation, 
as significant and/or rapid changes in the pH of a protein in solution can lead to the formation of 
aggregates.  A third, slightly different approach might consist of employing some form of post-
conjugation processing and “clean-up”—such as the separation and fractionation steps presented 
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earlier in this paper—to remove the more aggregated and less labeled population.  We could 
thereby enhance the population for a more equally labeled and narrower set of polydispersed 
conjugate proteins.  In addition to the approaches mentioned here, it is very likely that there are 
other alternative approaches that would prove effective in producing critical reagents with more 
uniform labeling; such approaches and their effects could be probed in a future set of related 
experiments.    
      In regards to future experiments of this nature, there are two important improvements 
that could be made to the testing protocols used here.  Due to cost constraints, as the ERT and 
dye conjugates used in the testing described in this work are either very expensive, very difficult 
to procure, or both, we were obliged to produce and work with smaller batches of conjugate than 
we may have otherwise liked.  Creating a much larger batch of conjugate likely would have 
proved useful, especially when quantifying the degrees of labeling for the conjugate population 
in each fraction.  Because some of the dispersed populations are very dilute in the overall 
conjugate sample, using more bulk conjugate should assist in determining the precise protein 
concentration of the most dilute populations more easily and accurately.  The method used to 
circumvent this issue during the testing described here was to test and average multiple sample 
replicates and dilutions to get the most precise concentration value possible.  However, simply 
having more protein per fraction would have made this step much simpler and more 
straightforward.   
The second, noticeably flawed aspect of the testing performed here was our inability to 
fully separate the polydispersed populations from one another during fractionation.  Without 
fully isolating the populations, the clarity of the trends identified and presented for each 
conjugate was very likely reduced from what we might predict to be their true, optimal levels.  If 
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the fractionation had been more complete, possibly by using a different column for the 
separation or a more optimized set of running parameters, it is assumed that the relationship 
between aggregation and degree of labeling would be even more pronounced than it was found 
to be during the testing presented in this thesis.   
Although, the level of enhancement attained between the dispersed populations found in 
the different fractions was more than sufficient to establish the presence of a strong, consistent 
trend, mitigating the shortcomings identified in the fractionation step to improve separation 
would likely have produced even more compelling results.  I would, however, still consider the 
testing quite successful, despite the flaws and potential improvements identified.  Any future 
research into this subject, incorporating the changes and improvements noted above, would be 
very interesting and should, I expect, produce strong supporting data.  
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Appendix I 
Definition of Terms 
 
Anti-Drug Antibody (ADA):  An antibody specifically raised against a 
biotherapeutic of interest. 
Challenge Ratio:  The ratio of conjugate to source protein used in a conjugation 
reaction. 
Critical Reagent:  “An essential component of a ligand-binding assay whose 
unique characteristics directly impact assay performance.” (Giest et al., 2013). 
Degree of Labeling (DOL):  The degree of labeling is a value that represents the 
average number of conjugates, or labels, per unit of protein in a protein conjugate. 
Enzyme Linked Immuno Assay (ELISA):  A plate-based assay technique 
designed to detect and quantify substances such as proteins and antibodies.  
Fractionation:  A separation process where a certain quantity of protein (enzymes, 
antibodies, peptides, etc.) is divided into smaller quantities, or fractions, based on 
a gradient.  
Immunogenicity:  The propensity of a treatment to cause an immune reaction in 
the patient.  
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Ligand-Binding Assay (LBA):  A ligand-binding assay is an analytical method 
that uses assay reagents with high binding affinity capable of binding a target 
analyte in a biological matrix. 
Size Exclusion High Chromatography (SEC):  An HPLC technique used to 
separate particles based on size. 
Source Protein:  A term referring to the unlabeled protein (to be conjugated in a 
conjugation reaction) prior to its use as a critical reagent in a ligand-binding 
method. 
